Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Italian university researchers investigate peptidomimetic HIV protease inhibitors

July 24, 1998

rhGH/rhIGF-1 therapy is tolerable and moderately improves HIV-specific immune function

July 24, 1998

MAb F105 is safe for use in AIDS patients

July 24, 1998

Canadian approval granted for first NNRTI for HIV/AIDS

July 23, 1998

First antisense drug recommended for approval by FDA advisory committee

July 23, 1998

Preclinical activity and resistance profile of S-1153, a new NNRTI

July 23, 1998

Use of Anticort in AIDS supported by new study

July 23, 1998

Enzo Biochem initiates phase I clinical trials of HIV-1 treatment

July 21, 1998

ZymeTx signs agreement for potential HIV antiviral technology

July 21, 1998

Chemokine receptor antagonist NSC-651016 shows potent anti-HIV activity in preclinical studies

July 20, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...